Invitation to Cantargia's Q1 2024 Interim Report Presentation on May 21 at 3 p.m. CEST

Cantargia AB, a biotechnology company based in Lund, Sweden, is set to release its interim report for the first quarter of 2024 on Tuesday, May 21, 2024, at 07:00 a.m. CEST. To mark the release of this report covering the period from January to March 2024, Cantargia has organized an audiocast with a teleconference, scheduled for the same day at 3:00 p.m. CEST. During the event, Cantargia's CEO, Göran Forsberg, and CFO, Patrik Renblad, will present the company's performance and offer comments on the interim report. This session will also include a Q&A segment.

Participants have the option to join via webcast or teleconference. Through the webcast, attendees will be able to submit written questions. For those opting to join via teleconference, registration is required to receive the necessary phone numbers and conference ID for access. The webcast will be available for on-demand viewing on Cantargia's corporate website after the live session.

Cantargia AB specializes in the development of antibody-based treatments targeting life-threatening diseases. The company has developed a platform centered around the protein IL1RAP, which is implicated in various forms of cancer and inflammatory diseases. The primary focus of Cantargia's research is on nadunolimab (CAN04), an antibody that is currently undergoing clinical trials mainly in combination with chemotherapy. The primary targets are pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Preliminary data from these studies suggest that the combination of nadunolimab with chemotherapy presents enhanced efficacy compared to chemotherapy alone.

In addition to nadunolimab, Cantargia is also advancing another antibody, CAN10. Unlike nadunolimab, CAN10 inhibits IL1RAP signaling through a different mechanism and is aimed at treating severe autoimmune and inflammatory diseases, with initial research focusing on systemic sclerosis and myocarditis.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!